乳腺癌新辅助治疗后活检与残留病灶间HER2表达的演变
该研究回顾性分析了2016年1月至2022年8月在Dana-Farber Brigham癌症中心接受新辅助治疗并手术的早期乳腺癌患者,评估治疗前后HER2表达变化。在1080例有残留病灶的患者中,29.5%出现HER2表达改变,且HER2-0或HER2-low肿瘤患者更易发生改变。HER2表达变化仅在初诊HER2阳性肿瘤中具有预后意义。
要点
- 新辅助治疗后29.5%的早期乳腺癌患者HER2表达发生改变。
- 初诊HER2-0或HER2-low肿瘤患者较HER2阳性患者更易出现HER2表达变化(32.3% vs 21.3%,p<0.001)。
- HER2表达变化仅在初诊HER2阳性肿瘤中与3年无复发生存相关(71.6% vs 89.6%,p=0.006)。
核心结论
- 近30%的早期乳腺癌患者在新辅助治疗后HER2表达发生改变,且该变化仅在初诊HER2阳性肿瘤转为HER2阴性时具有预后意义。
研究设计与样本
- 回顾性分析2016年1月至2022年8月在Dana-Farber Brigham癌症中心接受新辅助治疗并手术的连续早期乳腺癌患者,比较治疗前后样本的HER2表达。
主要发现
- 在1613例接受新辅助治疗的患者中,1080例手术时有残留病灶,其中319例(29.5%)HER2表达状态(HER2 0 vs HER2-low vs HER2阳性)发生改变,表达降低者占50.5%,升高者占49.5%。
- 基于蒽环类方案(31.8%)或紫杉类/铂类方案(32.4%)的患者HER2表达变化率相似。
- 初诊HER2-0或HER2-low肿瘤患者较HER2阳性患者更易发生HER2表达变化(32.3% vs 21.3%,p<0.001)。
- 在初诊HER2阳性肿瘤患者中,HER2表达变化与未变化者的3年无复发生存率分别为71.6% vs 89.6%(p=0.006);在初诊HER2阴性肿瘤患者中分别为79.3% vs 81.1%(p=0.31)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: We have previously found that HER2 expression is dynamic, and can change from the primary breast tumor to matched recurrences. With this work, we aimed to assess the dynamics of HER2 during neoadjuvant treatment.(NAT). METHODS: We reviewed HER2 expression in pre- and post-treatment samples from consecutive patients with early-stage breast cancer that received NAT and underwent surgery at Dana-Farber Brigham Cancer Center between 01/2016-08/2022. The primary outcome was evolution of HER2 expression from pre- to post-NAT specimens in patients with residual disease. RESULTS: Among 1613 patients receiving NAT, 1080 had residual disease at surgery. A total of 319 patients (29.5%) experienced a change in HER2 expression (HER2 0 vs. HER2-low vs. HER2-positive) from the pre-treatment sample to residual disease, with roughly equal distribution between decreased (50.5%) and increased HER2 expression (49.5%). Similar rates of change in HER2 expression were observed with anthracycline-based (31.8%) or taxane/platinum-based regimens (32.4%). Patients with HER2-0 or HER2-low tumors at diagnosis were likelier to experience a change in HER2 expression post-NAT compared to HER2-positive (32.3% vs. 21.3%, p < 0.001). Changes in HER2 expression post-NAT were prognostic among patients with HER2-positive tumors at diagnosis (3-year recurrence-free survival for change vs. no change: 71.6% vs. 89.6%, p = 0.006) but not among those with HER2-negative tumors at diagnosis (3-year recurrence-free survival for change vs. no change: 79.3% vs. 81.1%, p = 0.31). CONCLUSIONS: Nearly 30% of patients with early-stage breast cancer showed a change in HER2 expression after NAT. Changes in HER2 expression post-NAT were only prognostic in the setting of HER2-positive tumors becoming HER2-negative at surgery.
引用
- Tarantino P, Ajari O, Graham N, et al. Evolution of HER2 expression between pre-treatment biopsy and residual disease after neoadjuvant therapy for breast cancer. Eur J Cancer. 2024. PMID: 38368741. doi:10.1016/j.ejca.2024.113920
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。